Skip to main content
SpringerLink
Log in

Regarding: A global anti-B cell strategy combining obinutuzumab and daratumumab in severe pediatric nephrotic syndrome

  • Letter to the Editors
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

A Letter to the Editors to this article was published on 10 March 2021

The Original Article was published on 28 October 2020

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Dossier C, Prim B, Moreau C, Kwon T, Maisin A, Nathanson S, De Gennes C, Barsotti K, Bourrassi A, Hogan J, Deschênes G (2020) A global antiB cell strategy combining obinutuzumab and daratumumab in severe pediatric nephrotic syndrome. Pediatr Nephrol. https://doi.org/10.1007/s00467-020-04811-0

  2. Said R, Tsimberidou AM (2017) Obinutuzumab for the treatment of chronic lymphocytic leukemia and other B-cell lymphoproliferative disorders. Expert Opin Biol Ther 17:1463–1470

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Tam C, Kuss B, Opat S, Boulos J, Marlton P (2017) Management of patients with previously untreated chronic lymphocytic leukaemia with obinutuzumab and chlorambucil. Intern Med J 47(Suppl 4):5–10

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Intercollegiate Faculty of Biotechnology of the University of Gdańsk and the Medical, University of Gdańsk, Gdańsk, Poland

    Alan Majeranowski & Marcin Okrój

Authors
  1. Alan Majeranowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marcin Okrój
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alan Majeranowski.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Majeranowski, A., Okrój, M. Regarding: A global anti-B cell strategy combining obinutuzumab and daratumumab in severe pediatric nephrotic syndrome. Pediatr Nephrol 36, 1651–1652 (2021). https://doi.org/10.1007/s00467-021-04981-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-021-04981-5

Search

Navigation